I have extensive experience in the intersection of AI and biology, and currently am the founder and CEO at ReviveMed, an award-winning, AI-based metabolomic platform for precision medicine. During my PhD at MIT, I developed a groundbreaking artificial intelligence (AI) platform designed to tackle the challenges of characterizing vital small molecules like glucose and cholesterol in patients’ blood or tissues. This platform translates complex data into actionable insights for precision medicine. I founded ReviveMed to bring this innovative technology to market and make a meaningful impact on people's lives. Today, ReviveMed is an award-winning, venture-backed startup. Our AI platform can characterize metabolites at a capacity 20 times greater than existing methods, leading to discovering the right therapeutics for the right patients.Previously, I worked at leading research institutes, including ETH Zurich, and major pharmaceutical companies like Merck and Takeda Pharmaceuticals. My pioneering work has earned several prestigious awards and has been featured in various TV and media outlets. In 2019, I was honored as a TED fellow, joining a class of 20 visionaries, and I delivered a TED talk on the medical applications of AI and metabolomics, which has garnered nearly 2 million views. In 2020, MIT Technology Review recognized me as one of the top 35 innovators under 35 for my innovative AI-based technology to identify metabolites.
Listed skills include Systems Biology, Bioinformatics, Computational Biology, Machine Learning, and 6 others.